Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.

During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations on the third day of the meeting.

To accelerate the development of its own patch-based insulin pump, Tandem Diabetes has purchased AMF Medical.